Izotropic Corp. (TSE:IZO)
:IZO
IZO Stock Chart & Stats
C$0.28
C$0.01(8.33%)
At close: 4:00 PM EST
C$0.28
C$0.01(8.33%)
Day’s Range― - ―
52-Week RangeC$0.19 - C$0.49
Previous CloseN/A
Volume236.24K
Average Volume (3M)43.33K
Market Cap
C$15.18M
Enterprise ValueC$17.69M
Total Cash (Recent Filing)C$364.08K
Total Debt (Recent Filing)C$3.14M
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding68,984,680
10 Day Avg. Volume24,438
30 Day Avg. Volume43,328
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)-2.90
Price to Sales (P/S)0.00
P/FCF Ratio-22.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Niche Product FocusIzotropic’s singular focus on a dedicated breast CT platform aligns the company with a clear clinical niche: breast cancer screening and diagnostic imaging. A focused, product-led business model can concentrate R&D and commercialization resources, improving the odds of achieving durable clinical adoption if regulatory and reimbursement steps progress.
3D Imaging DifferentiationThe IzoView system’s 3D breast imaging capability is a structural technological differentiation versus standard 2D modalities. If clinical validation and practitioner uptake follow, 3D imaging can create a sustainable competitive advantage by addressing diagnostic gaps and embedding the device into multi-year imaging workflows.
Moderating Cash BurnReported moderation in cash burn versus prior years signals improving cost control and a lengthened runway relative to past multi‑million free cash outflows. Sustained lower negative cash flow eases near-term funding pressure and gives management more time to pursue clinical milestones or commercialization steps that affect long-term viability.
Bears Say
No RevenueThe absence of any trailing‑twelve‑month revenue is a fundamental constraint: without sales the company cannot demonstrate market demand, generate operating margins, or self‑fund commercialization. This structural lack of revenue means outcomes hinge on successful product approval, adoption, or continual external financing over the medium term.
Negative Equity & Weak Balance SheetNegative equity and a small asset base with meaningful debt indicate accumulated losses and impaired financial flexibility. Such a capital structure raises refinancing and solvency risk, making it harder to raise non‑dilutive capital and increasing the chance that future financing terms will be onerous if revenue or clear clinical milestones are not achieved.
Persistent Cash Flow DeficitsContinued negative operating and free cash flow, even if reduced, implies ongoing reliance on external capital. Persistent cash deficits constrain R&D and commercialization investment, elevate dilution or refinancing risk, and represent a durable execution challenge until the business generates positive operating cash or secures sustainable funding.
Izotropic News
IZO FAQ
What was Izotropic Corp.’s price range in the past 12 months?
Izotropic Corp. lowest stock price was C$0.19 and its highest was C$0.49 in the past 12 months.
What is Izotropic Corp.’s market cap?
Izotropic Corp.’s market cap is C$15.18M.
When is Izotropic Corp.’s upcoming earnings report date?
Izotropic Corp.’s upcoming earnings report date is Aug 21, 2026 which is in 134 days.
How were Izotropic Corp.’s earnings last quarter?
Izotropic Corp. released its earnings results on Mar 27, 2026. The company reported -C$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.004.
Is Izotropic Corp. overvalued?
According to Wall Street analysts Izotropic Corp.’s price is currently Overvalued.
Does Izotropic Corp. pay dividends?
Izotropic Corp. does not currently pay dividends.
What is Izotropic Corp.’s EPS estimate?
Izotropic Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Izotropic Corp. have?
Izotropic Corp. has 68,984,680 shares outstanding.
What happened to Izotropic Corp.’s price movement after its last earnings report?
Izotropic Corp. reported an EPS of -C$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.174%.
Which hedge fund is a major shareholder of Izotropic Corp.?
Currently, no hedge funds are holding shares in TSE:IZO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Izotropic Corp.
Izotropic Corporation, a MedTech company, commercializes diagnostic products for breast cancer. It develops and commercializes breast CT Imaging system; and 3D CT breast imaging platform for the earlier detection and diagnosis of breast cancer. The company was incorporated in 2016 and is headquartered in Surrey, Canada.
Technical Analysis
Spectral Medical
―
BioMark Diagnostics
―
Perimeter Medical Imaging AI
―
Sona Nanotech Inc
―
VentriPoint Diagnostics
―
Options Prices
Currently, No data available
---